BioLineRx Completes Treatment of First Patient in Phase I/II Cardiac Study
Posted on: Tuesday, 25 March 2008, 09:01 CDT
BioLineRx has announced that the first patient treated with BL-1040 was released from the Department of Cardiology at the University of Heidelberg in Germany, following treatment with no apparent adverse effects.
This was the first patient in a Phase I/II clinical trial study that is designed to assess the safety and feasibility of BL-1040 in up to 30 patients at several sites in Germany, Belgium, and Israel. The company expects to complete the first part of the trial towards the end of this year. BL-1040 is being developed as a class III medical device utilizing FDA's pre-marketing approval regulatory pathway approach.
Morris Laster, CEO of BioLineRx, said: "This is an important milestone in the development of BL-1040, BioLineRx's innovative product candidate, which is the first treatment that attempts to treat damaged cardiac tissue resulting from an acute myocardial infarction (MI) and addresses a tremendous unmet medical need. We plan to closely monitor this and future BL-1040 patients for safety."
Source: Datamonitor
Related Articles
- IKARIA(R) to In-License BioLineRx's BL-1040
- BioLineRx's BL-1040 Named One of 10 Most Promising Cardiovascular Projects By Windhover
- First Patient Successfully Undergoes Breakthrough Treatment for Acute Myocardial Infarction Developed By BioLineRx
- BioLineRx Presents BL-1040 Data at the American Heart Association Scientific Sessions 2007
- BioLineRx Presents BL-1040 Data at the Transcatheter Cardiovascular Therapeutics Conference
- BioLineRx Submits Application to Begin Pilot (Phase 1/2) Clinical Trials of BL-1040 to Treat Damaged Cardiac Tissue Following Acute MI
- BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
- BioLineRx In-Licenses Two Additional Drug Candidates From Tel Aviv University and the Technion and Achieves 2005 Goals
- BioLineRx Raises an Additional $9 Million and Advances Pipeline of Drug Candidates Toward Clinical Trials
 |
 |
User Comments (0)
RSS Feeds